



BLA 125268/S-167

**sBLA APPROVAL –  
ANIMAL EFFICACY**

Amgen Inc.  
Attention: Krystene Phan-Chronis, M.Sc.  
Senior Manager, Regulatory Affairs  
One Amgen Center Drive  
Thousand Oaks, CA 91320

Dear Ms. Phan-Chronis:

Please refer to your supplemental biologics license application (sBLA), dated July 28, 2020, received July 28, 2020, and your amendments, submitted under section 351(a) of the Public Health Service Act for Nplate (romiplostim) for injection, for subcutaneous use.

This “Prior Approval” efficacy supplement to your biologics license application seeks approval under the Animal Rule (21 CFR 601.90) for the indication of romiplostim to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]).

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, under the provisions of 21 CFR 601, Subpart H (Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible), effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,<sup>1</sup> that is identical to the enclosed labeling text for the Prescribing Information, and Medication Guide and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effectuated" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **SUBPART H APPROVAL REQUIREMENTS**

Approvals under 21 CFR Part 601, Subpart H (Approval of Biological Product When Human Efficacy Studies Are Not Ethical or Feasible) are subject to three requirements:

- (1) *Approval with restrictions to ensure safe use.* This subsection permits the Agency to require postmarketing restrictions as are needed to ensure safe use of the drug product, commensurate with the specific safety concerns presented by the drug product. We have concluded that Nplate (romiplostim) can be safely used without restrictions on distribution or use
- (2) *Information to be provided to patient recipients.* This subsection requires applicants to prepare labeling to be provided to patient recipients for drug products approved under this subpart. We have concluded that FDA approved patient labeling for Nplate (romiplostim) meets the requirement for this subsection.
- (3) *Postmarketing Studies.* This subsection requires you to conduct postmarketing studies, such as field studies, to verify and describe the biological product's clinical benefit and to assess its safety when used as indicated when such studies are feasible and ethical. We remind you of your postmarketing requirement specified in your submission dated July 28, 2020.

This requirement, along with any agreed upon completion dates, is listed below.

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

4008-1 A phase 4 observational study to evaluate the efficacy and safety of Nplate (romiplostim) in the setting of Hematopoietic syndrome of Acute Radiation Syndrome (HS-ARS) following acute exposure to myelosuppressive doses of radiation.

Draft Protocol Submission:	07/2021
Final Protocol Submission:	01/2022
Study Completion:	To be determined should an event occur
Final Report Submission:	To be determined should an event occur

Submit final reports to this BLA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated "**Subpart H Postmarketing Requirements.**"

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional studies are needed at this time.

### **PROMOTIONAL MATERIALS**

Under 21 CFR 601.45, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at (301) 796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 601.45, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated references, and approved Prescribing Information, Medication Guide, and Patient Package Insert (as applicable).

**U.S. Food and Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Mr. Frank Lutterodt, Regulatory Project Manager, at 301-796-4251.

Sincerely,

*{See appended electronic signature page}*

Libero Marzella, M.D., Ph.D.  
Director,  
Division of Imaging and Radiation Medicine  
Office of Specialty Medicine  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Medication Guide

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

LIBERO L MARZELLA  
01/28/2021 01:53:23 PM